

Letter No.: GLHRL/22/2022-23 Date: November 12, 2022

To,
Listing Compliance Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

SCRIPT CODE: 543520 ISIN: INE0J2K01014

Subject: Outcome of Meeting of Board of Directors held today i.e. Saturday, 12th day of November, 2022, in terms of Regulation 30 of SEBI (LODR) Regulations, 2015, for consideration and approval of Unaudited Financial Results for the Half Year ended on September 30, 2022.

Dear Sir/Madam,

In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that in the Board Meeting held today (i.e. Saturday, November 12, 2022), the Board of Directors of the Company has considered and approved the Unaudited Financial Results for the Half Year ended September 30, 2022 along with the Limited Review Report.

The above matter has been duly approved by the Board of Directors at their meeting which commenced at 01: 30 P.M. and concluded at 02: 30 P.M.

In this connection, we are enclosing herewith Unaudited Financial Results for the Half year ended on September 30, 2022, Limited Review Report and statement of uses of fund for your information and record. The same will be made available on the Company's website <a href="https://www.globalhospital.co.in">www.globalhospital.co.in</a>.

Kindly please take a note for the same and do the needful.

Thanking You,

Yours Faithfully,

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Encl: a/a



A division of

॥ सर्वे सन्तु निरामयाः ॥

Global Longlife Hospital and Research Limited Global Longlife Hospital & Research Ltd. Global Longlife Hospital and Research Limited Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380 054, Gujarat, India

#### UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED ON 30.09.2022

		(Rs. in Lakhs except per share data)				
Sr. No.			alf Year Ended			r Ended
	Particulars	30.09.2022	31.03.2022 Audited	30.09.2021 Audited	31.03.2022 Audited	31.03.2021 Audited
		Unaudited				
	Revenue from Operations	1,179.95	3,281.54	1,994.24	3,281.54	3,270.26
	Other Income	6.81	22.79	6.69	22.79	6.32
1	Total Income	1,186.77	3,304.33	2,000.93	3,304.33	3,276.59
2	Expenses					
	Operating (Direct) Expenses	525.76	1,364.18	736.15	1,364.18	1,285.04
	Purchase of Stock-in-Trade	53.73	367.51	276.15	367.51	720.30
	Changes in inventories of finished goods, work in progress and stock in	54.35	(7.06)	(15.32)	(7.06)	138.27
	Excise Duty			(	(,,,,,,	100.27
	Employee benefits expenses	181.61	406.06	170.74	406.06	341.63
	Finance Costs	20,41	139.89	9.19	139.89	243.18
	Depreciation and amortisation expenses	57.68	114.37	57.53	114.37	130.63
	Other Expenses	186.84	348.37	149.90	348.37	241.78
	Total Expenses	1,080.38	2,733.32	1,384.34		3,100.83
3	Profit/(Loss) before exceptional and extrordinary items and tax (1 - 2)	106.39	571.01	616.59		175.70
4	Exceptional Items	100.07	5/1.01	010.37	3/1.01	1/5./(
5	Profit/(Loss) before extraordinary item and tax (3 - 4)	106.39	571.01	616.59	571.01	175.76
6	Extraordinary Items	100,57	371.01	010.39	371.01	173.70
7	Profit/(Loss) before tax (5 - 6)	106.39	571.01	616.59	571.01	175.76
8	Tax Expense	100.53	371.01	010.59	371.01	173.70
	a) Current tax	17.76	95.30		95.30	
	b) Deferred tax	12.80	118.32		118.32	(28.94
	c) Excess/(Short) Provision Of Earlier Years	12.00	110.32	7	110.32	(28.94)
9	Net Profit/(Loss) from continuing activities after tax (7 - 8)	75.84	357.39	616.59	357.39	204.70
10	Net Profit/(Loss) from discontinued operations before tax	73.04	337.39	010.39	337.39	204.70
11	Tax Expense of discontinued operations		-	-	-	-
12	Net Profit/(Loss) from discontinued operations after tax (10-11)					
13	Net Profit/(Loss) for the period after tax (9 + 12)	75.84	357.39	616.50	257 20	204.70
	Other Comprehensive Income, net of tax (OCI)	73.04	357.39	616.59	357.39	204.70
	a) Items that will not be reclassified to profit or loss		-	-	-	
	b) Income tax relating to items that will not be reclassified to profit or loss		-	-	-	
	Total	-	-	-	-	
15	Total Comprehensive Income for the period (13+14)	75.84	357.39	(1( 50	255 20	204.70
	Details of Equity Share Capital	/5.04	357.39	616.59	357.39	204.70
	Paid-up Equity Share Capital	1,050.00	700.00	700.00	700.00	<b>5</b> 00.00
	Face Value of Equity Share Capital	1,030.00		700.00	700.00	700.00
	Reserves excluding revaluation reserves		10.00	10.00	10.00	10.00
	Basic earning (loss) per share from continuing and discountinued	5,621.96	996.22	1,284.66	996.22	667.70
	Diluted earning (loss) per share from continuing and discountinued	0.72	5.11	8.81	5.11	2.92
17	Debt Equity Ratio	0.72	5.11	8.81	5.11	2.92
	Debt Service Coverage Ratio	0.08	0.17	0.83	0.17	0.91
		4.80	3.01	5.06	3.01	2.67
	Interest Service Coverage Ratio	24.76	8.32	12.52	8.32	2.95

Dhruv Jani Managing Directo DIN: 03154680

search Limited

Date: 12.11.2022 Place: Ahmedabad

Notes:

The above results have been reviewed by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on November 12, 2022.

Previous year's/period's figure have been regrouped/rearranged wherever necessary.

AHMEDABAD

The results for the Half Year and year ended March 31, 2022 are available on the website of BSE Limited on www.bseindia.com and on company website on www.globalhospital.co.in

The company had used the fund of Initial Public offer as stated in the prospectus of the company and there is no deviation of fund as on September 30, 2022.

As the company is listed on SME Platform of BSE, It has been exempted from applicability of IND-AS as per proviso to rule 4 of Companies (Indian Accounting Standards) Rules, 2015.

As the company do not have any Holding/Subsidiary/Joint Venture/Associate concern, no reporting have been made In this regards.



# Global Longlife Hospital and Research Limited Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad 380 054, Gujarat, India

#### Statement of Assets and Liabilities

(Rs. in Lakhs)

	Particulars -	As At 30.09.2022	As At 30.09.2021	
	Tarticulars	Unaudited	Audited	
	Equity and liabilities			
1	Shareholders' funds			
	Share capital	1,050.00	700.00	
	Reserves and surplus	5,621.96	1,284.66	
	Money received against share warrants		-	
	Total shareholders' funds	6,671.96	1,984.66	
2	Share application money pending allotment			
3	Deferred government grants	-	-	
4	Minority interest	-		
5	Non-Current Liabilities			
	Long-term borrowings	282.12	1,164.45	
	Deferred tax liabilities (net)		- 1,101110	
	Foreign currency monetary item translation	_		
	Other long-term liabilities	4.95	30.00	
	Long-term provisions	-	4.96	
	Total Non-Current Liabilities	287.07	1,199.41	
6	Current Liablities			
	Short-term borrowings	251.21	485.56	
	Trade Payables			
-	(A) Total outstanding dues of micro enterprises and small enterprises.		-	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises.		MARI 80	
		79.69	109.48	
	Other current liabilities .	70.53	244.42	
4	Short-term provisions	32.61	1.13	
	Total current liabilities	434.04	840.59	
	Total equity and liabilities	7,393.07	4,024.67	





॥ सर्वे सन्तु निरामयाः ॥ A division of Global Longlife Hospital & Research Ltd. Assets Non-current assets (i) Fixed assets 1,705.69 1,619.37 Tangible assets Producing properties Intangible assets 0.44 0.44 Preproducing properties Tangible assets capital work-in-progress Intangible assets under development or work-in-progress Total fixed assets 1,706.13 1,619.82 Non-current investments 2,910.15 71.97 (ii) Deferred tax assets (net) 244.41 375.52 (v) Foreign currency monetary item translation (vi) difference asset account (vii) Long-term loans and advances 368.81 334.96 (viii) Other non-current assets Total non-current assets 3,489.51 816.30 Current assets Current investments 35.61 Inventories 33.92 96.54

For, Global Long to Propinal and Research Limited

BODAKSEV

Trade receivables

Other current assets

equivalents

Cash and cash equivalents

Short-term loans and advances

Bank balance other than cash and cash

Total current assets

Total assets

Dhruy Jani Managing Dire DIN: 03154680 Date: 12.11.2022 Place: Ahmedabad

1,198.04

921.94

94.22

2,283.74 7,393.07 1,023.00

7.58

375.12

1,502.24

4.024.67




Global Longlife Hospital and Research Limited Regd Office: Global Hospital, Opp. Auda Garden, Nr. Water Tank, Bodakdev, Ahmedabad - 380 054, Gujarat, India

### CASH FLOW STATEMENT FOR THE HALF YEAR ENDED ON 30TH SEPTEMBER, 2022

[Rs. in Lakhs]

	Particulars	Half Year Ended		
		30-09-2022	30-09-2021	
		Unaudited	Audited	
A.	CASH FLOW FROM OPERATING ACTIVITIES			
	Net Profit before taxation and extraordinery items	106.39	616.59	
	Adjustment for :-			
	Depreciation and Amortization	57.68	57.53	
	Foreign exchange loss			
	Short Term Capital Loss			
	Loss on fair valuation of MF - Ind AS			
	Interest Income	(5.08)	(3.57	
	Dividend income	(1.50)		
	Finance Costs	20.41		
	Advances Written off			
	provision for Doubtful Advance w/back, no longer required			
	MAT Credit Written off			
	Other adjustment to reconcile Profit	(0.10)	0.38	
		177.79	670.92	
	Operating Profit berfore working capital changes			
	Change in working Capital :			
	Adjustment for Decrease (Increase) in operating assets			
	Inventories	54.35	(15.32	
	Trade receivables	(307.33)	(238.92	
	Other Current Assets	(81.93)	(151.67	
	Short Term Loans & Advances	111.42		
	Other Non Current Asset	(10.86)		
	Adjustment for (Decrease) Increase in opearting liabilities			
	Trade payables	(348.17)	(216.76	
	Other current liabilities	(167.46)	33.34	
	Other long term liabilities	(31.06)		
	Non current provision	(5.81)		
	Short Term Provision	(28.70)	(0.06	
			(0.00	
	Cash Generated from Operations			
	Direct tax Paid	80.44		
	Income tax refund received			
4	Cash Flow before extraordinary items			
	Extraordinary Items/Prior Period Items			
	Net cash from Operating Activities	(718.19)	81.54	
		(710.13)	01104	
B.	NET CASH FLOW FROM INVESTMENT ACTIVITIES			
	Purchase of Property, Plant and Equipment	(6.18)	(17.69)	





A division of Global Longlife Hospital & Research Ltd.

	Purchase Of Investments or Equity Instruments		(24.94)
	Sale of Property, Plant and Equipment		
	Maturity of Term Deposits		
	Loans given		-
	Bank deposits not considered under Cash and cash equivalents	(25.36)	
	(Increase) / Decrease in Loans & Advances		7.33
	Long Term Capital Loss		
	Short Term Capital Loss		
	Short Term Capital Gain		63
	Purchase Of Investments	(2,900.15)	
	Long Term Capital Gain		
	Interest income	5.08	3.57
	Dividend Income	1.50	
	Proceeds from sale of fixed assets		
	Net Cash from Investment Activities	(2,925.11)	(31.73)
C.	CASH FLOWS FROM FINANCING ACTIVITIES		
	Repayment of Long Term Borrowings		(86.22)
	Proceeds from issue of equity share	4,900.00	(00.22)
	Finance Cost Expense	(20.41)	
	Proceeds of long term borrowings	(=0,11)	
	Repayment of long term borrowings		
	Non Current - financial loans		
	Repayment of current financial borrowing	(336.19)	
	Proceeds of short term borrowings	(550.13)	
	Net Cash from financial activities	4,543.41	(86.22
	NET INCREASE /(-) DECREASE IN CASH AND CASH EQUIVALENTS	900.11	(36.42)
	OPENING BALANCE IN CASH AND CASH EQUIVALENTS	21.83	44.00
	CLOSING BALANCE IN CASH AND CASH EQUIVALENTS	921.94	7.58

Note: Figure in brackets denote outflows.

For, Global Longlife Hospital and Research Limited

Dhruv Jani Managing Director DIN: 03154680

Date: 12.11.2022 Place: Ahmedabad



LIMITED REVIEW REPORT ON UNAUDITED HALF YEARLY STANDALONE FINANCIAL RESULTS OF COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REOUIREMENTS) REGULATIONS, 2015

To the Board of Directors of Global Longlife Hospital and Research Limited

We have reviewed the accompanying statement of unaudited financial results of **Global Longlife Hospital and Research Limited** for the period ended 30<sup>th</sup> September, 2022. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 12th November, 2022

For, KARMA&Co. LLP Chartered Accountants FRN No. 127544W/W100376

> CA Jignesh A. Dhaduk Designated Partner

M.No.129149

www.karmallp.in

UDIN: 22129149BCXBPB2589

■ Head Off.: 503, 5th Floor, "PATRON", Opp. Kensville Golf Academy, Rajpath Club to S P Ring Road,

Bodakdev, Ahmedabad - 380054 LLPIN : AAO-7574 Tel : 079 40394154 E-mail : ahd.office@karmallp.in

AHMEDABAD

SURAT MUMBAI RAJKOT

## Details of Utilization of Issue Proceeds

Details of Utilization of Issue Proceeds  Statement of Utilization of Money raised through Initial Public offer of Equity Shares as at September 30, 2022						
Sr. No.	Object as stated in the Prospectus	Amount proposed to be utilized	Actual amount utilized	(Rs. In Lakent Unutilized Amount		
1.	Acquire Land on Leasehold Basis	2,000.00	2,000.00	-		
2.	Repayment of Loan	1,480.00	1,480.00	-		
3.	General corporate purposes	1,070.00	1070.00	~		
4.	Public Issue Expense	350.00	350.00	-		
-	Total ·	4,900.00	4,900.00			

For, Global Longlife Hospital and Research Limited

Dhray Jani Managing Director

DIN: 03154680